期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

慢性髓性白血病的规范化诊治

Standardized diagnosis and treatment for chronic myelogenous leukemia
原文传递
导出
作者 江滨
机构地区 北京大学人民医院血液病研究所
出处 《中国实用内科杂志》 CAS CSCD 北大核心 2007年第14期1097-1100,共4页 Chinese Journal of Practical Internal Medicine
关键词 白血病 髓性 慢性 诊断 治疗 Leukemia, myelogenous, chronic Diagnosis Treatment
分类号 R5 [医药卫生—内科学]
  • 相关文献

参考文献10

  • 1江倩,陈珊珊,江滨,江浩,陆颖,丘镜莹,陆道培.Ph阳性慢性粒细胞白血病患者伊马替尼治疗后的Ph阴性异常克隆演变[J].中华血液学杂志,2005,26(1):23-26. 被引量：10
  • 2Iacobucci I,Saglio G,Rosti G,et al.Achieving a major molecular response at the time of a complete cytogenetic response predicts a better duration of CCyR in imatinib-treated chronic myeloid leukemia patients[J].Clin Cancer Res,2006,12:3037-3042. 被引量：1
  • 3Press RD,Love Z,Tronnes AA,et al.BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate treated patients with CML[J].Blood,2006,107:4250-4256. 被引量：1
  • 4Nardi V,Azam M,Daley GQ.Mechanisms and implications of imatinib resistance mutations in BCR-ABL[J].Curr Opin Hematol,2003,11:35 -43. 被引量：1
  • 5江倩,陈珊珊,江滨,江浩,陆颖,陆道培.伊马替尼治疗慢性粒细胞白血病加速期疗效评价[J].中华血液学杂志,2004,25(6):333-336. 被引量：15
  • 6Zonder JA,Pemberton P,Brandt H,et al.The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment[J].Clin Cancer Res,2003,9(6):2092 -2097. 被引量：1
  • 7秦亚溱,阮国瑞,刘艳荣,李金兰,付家瑜,王卉,常艳,江滨,江倩,江浩,丘镜滢,陈珊珊,陆道培.实时定量RT-PCR监测慢性粒细胞白血病患者伊马替尼治疗过程中bcr/abl mRNA水平[J].中华血液学杂志,2005,26(1):1-5. 被引量：12
  • 8Branford S,Rudzki Z,Parkinson I,et al.Real time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations[J].Blood,2004,104:2926-2932. 被引量：1
  • 9Davies SM,DeFor TE,McGlave PB,et al.Equivalent outcomes in patients with chronic myelogenous leukemia after early transplantation of phenotypically matched bone marrow from related or unrelated donors[J].Am J Med,2001,110:339-346. 被引量：1
  • 10Horowitz MM,Rowlings PA,Passweg JR.Allogeneic bone marrow transplantation for CML:a report from the International Bone Marrow Transplant Registry[J].Bone Marrow Transplant,1996,17(suppl 3):5 -6. 被引量：1

二级参考文献32

  • 1Druker BJ, Lydon NB. Lesssons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest,2000,105:3-7. 被引量：1
  • 2Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med,2001,344:1031-1037. 被引量：1
  • 3Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med, 2001,344:1038-1042 被引量：1
  • 4Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med, 2002 ,346:645-652 . 被引量：1
  • 5Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood, 2002,99:1928-1937. 被引量：1
  • 6le Coutre P,Tassi E,Varella-Garcia M, et al. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood, 2000,95:1758-1766. 被引量：1
  • 7Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science, 2001,293:876-880. 被引量：1
  • 8Thiesing JT, Ohno-Jones S, Kolibaba KS, et al. Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells. Blood, 2000,96:3195-3199. 被引量：1
  • 9Kano Y, Akutsu M, Tsunoda S, et al. In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood, 2001,97:1999-2007. 被引量：1
  • 10Topaly J, Zeller WJ, Fruehauf S. Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells. Leukemia, 2001,15:342-347. 被引量：1

共引文献34

中国实用内科杂志
2007年 第14期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部